Nisa Investment Advisors LLC Sells 2,914 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Nisa Investment Advisors LLC reduced its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 86.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 454 shares of the biotechnology company’s stock after selling 2,914 shares during the period. Nisa Investment Advisors LLC’s holdings in Blueprint Medicines were worth $29,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CWM LLC bought a new stake in shares of Blueprint Medicines during the 4th quarter worth approximately $34,000. Exane Derivatives raised its position in Blueprint Medicines by 1,340.7% during the 4th quarter. Exane Derivatives now owns 389 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 362 shares in the last quarter. Covestor Ltd bought a new stake in Blueprint Medicines during the 4th quarter valued at $46,000. Benjamin F. Edwards & Company Inc. raised its position in Blueprint Medicines by 19.8% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 906 shares of the biotechnology company’s stock valued at $97,000 after purchasing an additional 150 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in Blueprint Medicines by 15.2% during the 4th quarter. Van ECK Associates Corp now owns 1,335 shares of the biotechnology company’s stock valued at $143,000 after purchasing an additional 176 shares in the last quarter. 99.69% of the stock is owned by institutional investors.

Blueprint Medicines Trading Down 1.8 %

BPMC opened at $51.06 on Monday. Blueprint Medicines Co. has a 12-month low of $43.46 and a 12-month high of $117.86. The firm has a market capitalization of $3.04 billion, a PE ratio of -4.62 and a beta of 0.99. The firm has a 50 day moving average of $53.77 and a two-hundred day moving average of $61.76.

Blueprint Medicines (NASDAQ:BPMCGet Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The biotechnology company reported ($1.79) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.79). Blueprint Medicines had a negative net margin of 293.97% and a negative return on equity of 35.24%. The company had revenue of $62.70 million during the quarter, compared to analyst estimates of $39.98 million. During the same period last year, the firm posted ($1.72) EPS. Blueprint Medicines’s revenue for the quarter was up 190.3% compared to the same quarter last year. As a group, analysts predict that Blueprint Medicines Co. will post -7.59 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on BPMC shares. Stifel Nicolaus decreased their target price on Blueprint Medicines from $98.00 to $90.00 in a research report on Friday, July 1st. HC Wainwright restated a “buy” rating and set a $100.00 price objective on shares of Blueprint Medicines in a research note on Friday, June 10th. JMP Securities reiterated a “buy” rating and issued a $152.00 target price on shares of Blueprint Medicines in a research note on Thursday, June 9th. Oppenheimer began coverage on shares of Blueprint Medicines in a report on Thursday, July 7th. They issued an “outperform” rating and a $80.00 price target on the stock. Finally, SVB Leerink lowered their price target on shares of Blueprint Medicines from $60.00 to $56.00 and set a “market perform” rating on the stock in a report on Friday, July 1st. Two analysts have rated the stock with a sell rating, four have issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $88.86.

Insider Activity

In other news, insider Percy H. Carter sold 1,908 shares of Blueprint Medicines stock in a transaction that occurred on Monday, June 6th. The shares were sold at an average price of $59.76, for a total transaction of $114,022.08. Following the completion of the transaction, the insider now directly owns 28,685 shares of the company’s stock, valued at approximately $1,714,215.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 3.34% of the company’s stock.

About Blueprint Medicines

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Read More

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Want More Great Investing Ideas?

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.